442 related articles for article (PubMed ID: 37062051)
21. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
22. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
Patnaik MM; Tefferi A
Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
[TBL] [Abstract][Full Text] [Related]
23. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
24. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
26. Detection of the KIT
Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
[TBL] [Abstract][Full Text] [Related]
27. Mutations in epigenetic regulators in myelodysplastic syndromes.
Nikoloski G; van der Reijden BA; Jansen JH
Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
[TBL] [Abstract][Full Text] [Related]
28. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
29. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
Binder M; Carr RM; Lasho TL; Finke CM; Mangaonkar AA; Pin CL; Berger KR; Mazzone A; Potluri S; Ordog T; Robertson KD; Marks DL; Fernandez-Zapico ME; Gaspar-Maia A; Patnaik MM
Nat Commun; 2022 Mar; 13(1):1434. PubMed ID: 35301312
[TBL] [Abstract][Full Text] [Related]
31. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
32. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
33. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
Fang X; Xu S; Zhang Y; Xu J; Huang Z; Liu W; Wang S; Yen K; Zhang W
Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612
[TBL] [Abstract][Full Text] [Related]
34. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
35. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
[TBL] [Abstract][Full Text] [Related]
36. Clonal evolution and hierarchy in myeloid malignancies.
Takahashi K; Tanaka T
Trends Cancer; 2023 Sep; 9(9):707-715. PubMed ID: 37302922
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Epigenetic Modifications in Myeloid Malignancies.
Venney D; Mohd-Sarip A; Mills KI
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
[TBL] [Abstract][Full Text] [Related]
39. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
40. The role of mutations in epigenetic regulators in myeloid malignancies.
Shih AH; Abdel-Wahab O; Patel JP; Levine RL
Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
